Working Capital Highlights
As of September 30, 2007, ViroPharma's working capital was $573.3 million, which represents a $306.9 million increase from December 31, 2006, $31.2 million of which occurred in the third quarter of 2007. The nine month increase is primarily the result of the senior convertible notes issued on March 26, 2007 and cash flows.
Looking ahead in 2007
ViroPharma is updating previously announced guidance for the year 2007 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.
For the year 2007, ViroPharma anticipates the following:
-- Net product sales are expected to be between $202 to $208 million;
-- Gross margin rate for Vancocin is expected to be consistent with our
actual results in the first nine months of 2007;
-- Research and development (R&D) and marketing, general and
administrative (MG&A) expenses, excluding the impact of SFAS 123R, are
expected to be between $68 to $73 million.
-- The SFAS 123R impact to the above expenses will be approximately $8
million. Including the impact of SFAS 123R, the research and
development (R&D) and marketing, general and administrative (MG&A)
expenses are expected to be between $76 and $81 million.
|SOURCE ViroPharma Incorporated|
Copyright©2007 PR Newswire.
All rights reserved